Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis Article

sustainable development goals

publication date

  • July 1, 2016

webpage

published in

keywords

  • ESTEEM
  • PSOR-005
  • apremilast
  • difficult to treat
  • moderate to severe
  • palmoplantar psoriasis
  • palms
  • soles

start page

  • 99

end page

  • 105

volume

  • 75

issue

  • 1